Compare Nike Inc (NKE) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nike Inc vs Natera Inc. Common Stock — how do they compare? Nike Inc trades at $35.07 (market cap $52.48B), while Natera Inc. Common Stock trades at $394 (market cap $57.03B). The key difference: Nike Inc and Natera Inc. Common Stock are close in size by market cap, and Nike Inc pays a 4.64% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nike Inc for 155 Days and Natera Inc. Common Stock for 0 Days on average.
| NKE | NTRA | |
|---|---|---|
Market Cap | $52.48B | $57.03B |
Volume | 30,189,626 | 1,131,157 |
Sector | Consumer Cyclical | Health |
52-Week High | $69.68 | $425.64 |
52-Week Low | $33.87 | $179.42 |
Typical Hold Time | 155 Days | 0 Days |
Enterprise Value | $55.18B | $56.18B |
Dividend Yield | 4.64% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nike (NKE) trades at $35.35, up 1.84% with a bearish technical signal despite recent earnings beats. The stock faces headwinds from declining revenue ($46.31B in 2025 vs. $51.4B in 2024) and compressed margins (net margin 6.74%), though valuation appears reasonable with P/E of 16.9. Analyst consensus remains mixed with 47% buy ratings but a $36.80 price target suggesting limited upside. Recent news highlights inventory challenges and China market pressures.
Nike's turnaround strategy focuses on inventory discipline and digital DTC growth, but execution risks persist amid weak consumer demand. The stock offers moderate value at current levels with dividend support, though revenue stabilization is critical for sustained recovery. Near-term catalysts include Q4 2026 earnings on June 30, 2026.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Nike Inc
NIKE, Inc. designs, develops, and markets athletic footwear, apparel, equipment, and accessory products for men, women, and children. The Company sells its products worldwide to retail stores, through its own stores, subsidiaries, and distributors.
Read more on NKE →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
